semaglutide liver damage targets MASH molecular pathways beyond weight loss Tirzepatide vs Semaglutide Liver Damage
Description
doi: 10.1161/CIRCULATIONAHA.125.074545 Summary Keywords cardiovascular outcomes, SGLT2 inhibitors, GLP-1 agonists, combination therapy, heart failure, renal outcomes Citation Aristizbal-Colorado D, Corredor-Rengifo D, Sierra-Castillo S, Lpez-Corredor C, Vernaza-Trujillo D-A, Weir-Restrepo D, Izquierdo-Condoy JS, Ortiz-Prado E, Rico-Fontalvo J, Gmez-Mesa J-E, Abreu-Lomba A and Rivera-Martnez W-A (2025) A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists a comprehensive review
As the heart pumps less fluid through a progressively lighter frame, cardiovascular compensation mechanisms lag behind metabolic changes
doi:10.1056/NEJMoa2206038 Reddit - Dive into anything
Weeks 13 through 16: Reduce to 5 mg weekly
